Make a donation

Friday, May 28, 2021

Pomalyst (pomalidomide) and Thalomid (thalidomide) - Assessing the potential risk of progressive multifocal leukoencephalopathy

 A summary safety review (SSR) regarding Pomalyst (pomalidomide) and Thalomid (thalidomide) and the potential risk of progressive multifocal leukoencephalopathy (PML) has been published by Health Canada. The SSR is intended to provide Canadians with a sufficient understanding of the safety review conducted by Health Canada, specifically what was assessed, what was found and what action was taken.

Read the Summary Safety Review